EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Liquid biopsy biomarkers in breast cancer: An overview of systematic reviews

Bizhar Ahmed Tayeb, Alaa Am Osman, Isaac Kinyua Njangiru

Clinica Chimica Acta · 2025-01 · 566 · 120063

DOI: 10.1016/j.cca.2024.120063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinica Chimica Acta, 2025-01. Verfasst von Bizhar Ahmed Tayeb und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged 6720, Hungary. Electronic address: bizhar@dr.com. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the leading type of cancer affecting women globally and remains a significant cause of death. The diagnostic accuracy of liquid biopsy (LB) in the diagnosis of BC has not been well established. This overview synthesizes and critically evaluates the diagnostic test accuracy (DTA) of LB biomarkers in individuals with BC. Of 433 systematic reviews, eleven were included, assessing Fourier transform infrared (FTIR) spectroscopy, circulating tumor cells (CTCs), cell-free DNA (cfDNA), and microRNAs (miRNAs). The overall methodological quality of most of the reviews included was rated as critically low (n = 9, 81.8 %), and the remaining reviews were ranked as low and moderate. Key findings include CTCs with moderate sensitivity (0.50, 95 % confidence interval (CI) 0.48-0.52) and high specificity (0.93, 95 % CI: 0.92-0.95) with moderate certainty; cfDNA assays with high sensitivity (0.71-0.86) and specificity (0.88) with high certainty; FTIR assays with high sensitivity (0.97, 95 % CI: 0.94-0.96) and specificity (0.92, 95 % CI: 0.88-0.95) but low certainty. The miRNAs showed moderate to high sensitivity, while miR-21 had high specificity. Our overview indicates that identified liquid biopsies could serve as valuable tools for the diagnosis of breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorBreast NeoplasmsFemaleHumansCell-Free Nucleic AcidsLiquid BiopsyMicroRNAsNeoplastic Cells, CirculatingSystematic Reviews as Topic

Stichwörter der Autor:innen

Cancer biomarkersClinical utilityDiagnostic accuracyLiquid biopsyNon-invasive testingQuality assessment

Substanzen

Biomarkers, TumorCell-Free Nucleic AcidsMicroRNAs

Autor:innen und Institutionen

  • Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged 6720, Hungary. Electronic address: bizhar@dr.com.
  • Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged 6720, Hungary; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, University of Gezira, Wad Madan…
  • Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged 6720, Hungary; Department of Chemistry and Biochemistry, School of Science and Applied Technology, Laikipia University, Ny…

Zitieren

APA

Tayeb, B. A., Osman, A. A., & Njangiru, I. K. (2025). Liquid biopsy biomarkers in breast cancer: An overview of systematic reviews. Clinica Chimica Acta, 566, 120063. https://doi.org/10.1016/j.cca.2024.120063

Vancouver

Tayeb BA, Osman AA, Njangiru IK. Liquid biopsy biomarkers in breast cancer: An overview of systematic reviews. Clinica Chimica Acta. 2025;566:120063. doi:10.1016/j.cca.2024.120063

BibTeX
@article{Tayeb2025,
  author = {Tayeb, Bizhar Ahmed and Osman, Alaa Am and Njangiru, Isaac Kinyua},
  title = {Liquid biopsy biomarkers in breast cancer: An overview of systematic reviews},
  journal = {Clinica Chimica Acta},
  year = {2025},
  volume = {566},
  pages = {120063},
  doi = {10.1016/j.cca.2024.120063}
}
Kostenlos starten →